News | May 14, 2024
Lonza reports softer performance in Q1 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom
His resignation would be effective from March 18, 2024
The company has raised US$4.5 million in funding for its AI operating system
Investment is additive to KKR’s existing health care growth strategy
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Subscribe To Our Newsletter & Stay Updated
